Analysis | Number of comparisons | Pooled rate ratio, 95% CI | I2 (%) |
---|---|---|---|
General community dwellers | |||
Random effects meta-analysis all comparisons | 69 | 0.79 (0.73 to 0.85) | 47 |
Fixed-effect meta-analysis all comparisons | 69 | 0.82 (0.79 to 0.86) | 47 |
Random effects meta-analysis studies n>200 | 27 | 0.81 (0.75 to 0.89) | 52 |
Random effects meta-analysis studies PEDro score ≥7* | 24 | 0.81 (0.74 to 0.89) | 30 |
Random effects meta-analysis no computed analyses† | 28 | 0.76 (0.69 to 0.83) | 46 |
Random effects meta-analysis no cluster trials | 62 | 0.78 (0.72 to 0.85) | 49 |
Residential care dwellers | |||
Random effects meta-analysis all comparisons | 15 | 0.90 (0.72 to 1.12) | 68 |
Fixed-effect meta-analysis all comparisons | 15 | 0.98 (0.88 to 1.08) | 68 |
Random effects meta-analysis studies n>200 | 3 | 1.01 (0.77 to 1.33) | 74 |
Random effects meta-analysis studies PEDro score ≥7* | 4 | 0.82 (0.57 to 1.19) | 48 |
Random effects meta-analysis no computed analyses | 1 | 0.82 (0.49 to 1.38) | – |
Random effects meta-analysis no cluster trials | 14 | 0.92 (0.77 to 1.10) | 65 |
Clinical populations (community dwellers) | |||
Parkinson's disease, all trials | 6 | 0.47 (0.30 to 0.73) | 65 |
Parkinson's disease, PEDro score ≥7* | 4 | 0.44 (0.23 to 0.83) | 79 |
Stroke, all trials‡ | 3 | 0.74 (0.42 to 1.32) | 39 |
Cognitive impairment, all trials | 3 | 0.55 (0.37 to 0.83) | 21 |
Cognitive impairment, PEDro score ≥7* | 2 | 0.50 (0.40 to 0.61) | 0 |
After hospital discharge, all trials‡ | 3 | 1.16 (0.88 to 1.52) | 47 |
*Coded using PEDro rating scale.14
†Rate ratios used were those reported by the trial authors (ie, excluded were trials with rate ratios calculated by the review authors).
‡All trials had a PEDro score ≥7.